Skip to search formSkip to main contentSkip to account menu

oxamflatin

Known as: (2E)-N-Hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2-penten-4-ynamide, N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2E-penten-4-ynamide, (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid 
An inhibitor of histone deacetylase. It is an aromatic sulfonamide hydroxamate initially found in a screen for inhibitors of the tumorigenic… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Hydroxamic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines.
Ovarian epithelial carcinoma is the leading cause of deaths from gynecologic malignancy. New reagents with therapeutic potentials… 
2013
2013
Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
2012
2012
latent EBV and sensitize lymphoma cells to nucleoside antiviral agents Histone deacetylase inhibitors are potent inducers of gene expression in
http://bloodjournal.hematologylibrary.org/content/119/4/1008.full.html Updated information and services can be found at: (1291… 
2010
2010
A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients.
2006
2006
Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study.
2006
2006
Conformational analogues of Oxamflatin as histone deacetylase inhibitors.
Conformational analogues of the hydroxamic acid Oxamflatin compounds, have been synthesised to enable evaluation of the impact of… 
2006
2006
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
Histone deacetylase (HDAC) inhibitors have been actively exploited as potential anticancer agents. To identify gene targets of… 
2004
2004
Novel inhibitors of urokinase‐type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines
The plasminogen‐activating (PA) and matrix metalloproteinase (MMP) enzyme systems are implicated in proteolytic turnover of the… 
2000
2000
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity.
1996
1996
Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD.
In the course of screening for inhibitors of tumorigenic phenotype of K-ras-transformed NIH3T3 cells (DT cells), we found a novel… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)